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Cancer is responsible for a great propor-
tion of mortality and disease burden in 
the population. In 2010, cancer accounted 
for 26.2% of all cases of death in Germany, 
making it the second most common cause 
of death (after cardiovascular diseases at 
41.1%) [1]. As cancer is increasingly com-
mon later in life, demographic changes 
mean that certain types of cancer increase 
with the growing proportion of the elder-
ly [2]. On the other hand, cancer mortali-
ty rates (age-standardised death rates) are 
decreasing overall, and the chances of sur-
vival for cancer patients have significantly 
improved in recent decades. This is large-
ly due to the progress made in cancer ther-
apy but also to the early detection of can-
cer [3]. The aim of cancer screening tests 
is to detect the disease at the earliest pos-
sible stage. This permits early commence-
ment of a suitable therapy and hence gen-
tle treatment with a better chance of suc-
cess. Screening tests for common types of 
cancer have been offered as part of stat-
utory health insurance for over 30 years. 
The cancer screening services target age- 
and sex-specific groups in which the rel-
evant types of cancer are more prevalent. 
Statutory health insurance currently cov-
ers screening for cervical cancer, breast 
cancer, prostate cancer, colon cancer and 
skin cancer [4].
The World Health Organization 
(WHO) has defined criteria and guide-
lines for screening tests [5]. Based on these 
criteria, statutory health insurance on-
ly covers screening tests if effective treat-
ment for the relevant type of cancer exists 
and if it can be unequivocally diagnosed 
in the development or early disease stage 
by means of diagnostic measures. Fur-
thermore, sufficient physicians and facil-
ities must be available to secure the diag-
nosis and carry out the treatment [6].
From population-related surveys and 
the payment data of health insurers, it is 
known that a growing number of people 
in Germany are not only aware of the ex-
isting cancer screening services but al-
so participate in them. However, it is 
still the case that only part of the popu-
lation is reached. Age, sex, the level of ed-
ucation/socioeconomic status, partner-
ship, children, health condition and util-
isation of GP health care services [7, 8, 9, 
10] are seen as determinants that can in-
fluence the extent to which screening pro-
grammes are used. For the success of can-
cer screening programmes—in terms of 
reducing the disease burden and mortality 
at the population level—awareness, accep-
tance and willingness to undergo cancer 
screening tests are decisive factors within 
the various target groups.
The aim of the current analysis is to 
provide an overview of the awareness, 
knowledge and participation in cancer 
screening programs within the German 
population and to discuss possible influ-
encing factors. For this purpose, data from 
the first wave of the “German Health In-
terview and Examination Survey for 
Adults” (DEGS1) conducted by the Robert 
Koch Institute (RKI) were analysed. The 
focus was on the types of cancer screen-
ing that are offered to men and women by 
statutory health insurance.
Methods
The “German Health Interview and Ex-
amination Survey for Adults” (DEGS) is 
part of the health monitoring system at 
the Robert Koch Institute (RKI). The con-
cept and design of DEGS have been de-
scribed in detail elsewhere [11, 12, 13, 14, 
15]. The first wave (DEGS1) was conduct-
ed between 2008 and 2011 and comprised 
interviews, examinations and tests [16, 
17]. The target population comprises the 
residents of Germany aged 18–79 years. 
DEGS1 has a mixed design that permits 
both cross-sectional and longitudinal 
analyses. For this purpose, a random sam-
ple from local population registries was 
drawn to complete the participants of the 
“German National Health Interview and 
Examination Survey 1998” (GNHIES98) 
who re-participated. A total of 8,152 per-
sons participated, including 4,193 first-
time participants (response rate 42%) and 
3,959 revisiting participants of GNHIES98 
(response rate 62%). In all, 7,238 persons 
attended one of the 180 examination cen-
tres, and 914 were interviewed only. The 
net sample (n=7,988) permits represen-
tative cross-sectional analyses and time 
trend analyses to be performed for the age 
range of 18–79 years in comparison with 
GNHIES98 (n=7,124) [15]. The data of the 




The cross-sectional and trend analy-
ses are carried out with a weighting fac-
tor that corrects deviations in the sample 
from the population structure (as of 31 
December 2010) with regard to age, sex, 
region and nationality, as well as com-
munity type and education [15]. A sep-
arate weighting factor was prepared for 
the examination part. Calculation of 
the weighting factor also considered the 
re-participation probability of the GN-
HIES98 participants, based on a logis-
tic regression model. For the purpose of 
conducting trend analyses, the data from 
GNHIES98 were age-adjusted to the pop-
ulation level as of 31 December 2010. A 
non-response analysis and a comparison 
of selected indicators with data from cen-
sus statistics indicate a high level of rep-
resentativity of the net sample in the res-
ident population of Germany aged 18–
79 years [15].
To take into account both the weight-
ing as well as the correlation of the partici-
pants within a community, the confidence 
intervals were determined with SPSS-20 
procedures for complex samples. Differ-
ences were regarded as statistically signif-
icant if the respective 95% confidence in-
tervals did not overlap.
For the analyses of participation in 
cancer screening, information from the 
computer-assisted personal interview 
(CAPI) was used (n=7,988). In this in-
terview, participants were asked whether 
they are aware that participation in can-
cer screening is recommended by health 
insurers and whether they regularly un-
dergo such screening. They were then 
asked whether they had ever undergone 
screening for cancer in specific locations. 
If the answer was yes, participants were 
asked when the last screening test had 
taken place. Participants had a choice of 
five possible answers: time periods from 
“within the last 12 months” to “more than 
10 years ago”. With these answer cate-
gories, it was possible to assess wheth-
er the last specific cancer screening test 
was conducted within the recommend-
ed examination interval. This aspect is 
the focus of the analysis presented here. 
The information on participation in the 
various cancer screening tests (presented 
in . Tab. 1) was collected in DEGS1 and 
subsequently analysed.
Additionally, in DEGS1, men from the 
age of 45 years were asked whether they 
had undergone a so-called PSA test with-
in the specified time periods. This test to 
determine the prostate-specific antigen 
(PSA) is not included in the services of-
fered by statutory health insurance for the 
early detection of prostate cancer, since 
there is still international controversy sur-
rounding the test [18].
The descriptive analyses are limited in 
each case to the various age- and sex-spe-
cific groups of participants. This results in 
different sample sizes for the individual 
questions. Additionally, the associations 
between the variables age, sex and socio-
economic status (SES) were investigated. 
SES was determined using an index that 
includes information on school education 
Tab. 1 Cancer screening tests offered by statutory health insurance and covered by DEGS1. (Joint Federal Committee [4])
Goal of cancer screening Type of examination Target group Age Examination interval
Early detection of skin cancer Whole-body skin examination Women, men From 35 years Every 2 years
Early detection of colon cancer Stool examination (rapid test for occult, i.e. hidden, 
blood in the stool)
Women, men From 50 to 54 years Annually
From 55 years Every 2 years
Colonoscopy Women, men From 55 years Two colonoscopies at 
an interval of 10 years
Early detection of cervical cancer Cervical smear test Women From 20 years Annually
Early detection of breast cancer Breast palpation Women From 30 years Annually
Mammography as part of the national mammog-
raphy screening programme
Women From 50 to 69 years Every 2 years
Early detection of prostate cancer Prostate palpation (digital rectal examination) Men From 45 years Annually
Tab. 2 Awareness of the recommendations of statutory health insurance regarding participation in cancer screening, categorised by sex, age 





18–29 30–39 40–49 50–59 60–69 70–79 Total
Wom-
en
Total 74.0 (69.8–77.9) 78.8 (73.8–83.0) 91.0 (87.4–93.6) 96.8 (95.2–97.9) 98.0 (96.3–98.9) 93.6 (90.3–95.8) 88.5 (87.0–89.9)
Low 61.2 (50.8–70.7) 51.7 (34.2–68.7) 76.4 (62.4–86.4) 91.6 (83.9–95.8) 96.6 (91.8–98.6) 88.2 (81.5–92.7) 78.8 (74.3–82.8)
Medium 76.6 (71.2–81.3) 82.1 (75.9–86.9) 94.6 (91.4–96.7) 98.3 (96.6–99.1) 98.3 (96.4–99.2) 96.1 (92.4–98.1) 91.0 (89.4–92.4)
High 84.0 (70.6–91.9) 89.3 (83.3–93.3) 92.7 (86.4–96.2) 97.3 (93.3–98.9) 98.4 (91.9–99.7) 100 (100.0–100.0) 92.7 (89.9–94.8)
Men Total 45.2 (40.5–50.0) 62.4 (56.2–68.1) 79.5 (74.5–83.7) 91.2 (88.2–93.4) 92.9 (90.4–94.8) 92.3 (89.6–94.4) 75.7 (73.6–77.8)
Low 40.0 (29.0–52.1) 40.2 (26.8–55.3) 65.8 (51.6–77.6) 84.4 (75.8–90.4) 91.9 (85.1–95.8) 88.7 (78.6–94.4) 66.7 (61.6-71.5)
Medium 43.6 (38.1–49.3) 64.7 (56.4–72.1) 82.4 (76.2–87.3) 92.1 (88.2–94.8) 91.6 (87.6–94.4) 92.8 (89.0–95.1) 75.8 (72.9–78.5)
High 59.5 (45.5–72.1) 75.7 (66.3–83.2) 83.4 (75.5–89.1) 94.2 (89.5–96.9) 96.5 (93.2–98.2) 96.8 (92.5–98.6) 84.3 (80.8–87.3)





and vocational training, professional sta-
tus and net household income (weighted 
by household needs) and which enables 
a classification into low-, medium- and 
high-status groups [19].
Results
Awareness of the 
recommendations of statutory 
health insurers to participate 
in cancer screening
In all, 88.5% of women and 75.7% of men 
interviewed were aware of the recom-
mendations of statutory health insurers 
regarding participation in cancer screen-
ing programmes. The percentage of wom-
en and men who are aware of these rec-
ommendations increased with age (up 
to 69 years). Younger women and men 
in particular are not aware of the screen-
ing services offered. A social gradient was 
noted in the level of awareness in wom-
en of the age groups up to 59 years. The 
proportion of women who are aware of 
these recommendations is significant-
ly lower for women with low SES than 
it is for those with medium or high SES 
(. Tab. 2).
Regularity of participation 
in cancer screening
According to the survey, 67.2% of wom-
en (from the age of 20 years) and 40.0% 
of men (from the age of 35 years) reg-
ularly participate in cancer screening 
(. Tab. 3). Another 16.2% of women 
and 19.2% of men also undergo cancer 
screening tests but only irregularly (da-
ta not shown). Among men, the pro-
portion of regular participants increas-
es with age (up to 69 years). For women, 
the proportion of regular participants 
increases up to the age of 59 years and 
peaks between 50 and 69 years. In this 
age group, over three quarters of wom-
en indicated that they participate reg-
ularly in cancer screening. It should be 
noted that this age group is also the tar-
get group of the national mammography 
screening programme, i.e. women who 
are invited for cancer screening regularly 
every 2 years. With the exception of 50- 
to 69-year-old women, the proportion of 
those who regularly participate in can-
cer screening is significantly higher for 
women with a high SES than for women 
with a low SES. For men, participation in 
cancer screening does not show any so-
cial gradient.
Participation in special 
cancer screening tests
Early detection of skin cancer
In all, 25.8% of women and 22.9% of men 
aged 35 years and older underwent a 
whole-body examination of their skin for 
skin cancer screening within the 2 years 
before the interview (. Tab. 4). For men, 
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Participation in cancer screening programmes. 
Results of the German Health Interview and 
Examination Survey for Adults (DEGS1)
Abstract
A growing number of people in Germany 
participate in the cancer screening servic-
es offered by statutory health insurance. Us-
ing data from the first wave of the German 
Health Interview and Examination Survey for 
Adults (DEGS1), current levels of participa-
tion in cancer screening services were deter-
mined. DEGS1 (2008–2011) permits repre-
sentative cross-sectional analyses to be per-
formed. In DEGS1, persons who were entitled 
to different cancer screening services were in-
terviewed on their awareness, participation 
and regular utilisation of cancer screening 
for different types of cancer. Overall, 67.2% 
of women and 40.0% of men participate reg-
ularly. Participation rates fluctuate to a great 
extent for individual types of cancer screen-
ing. Women participate in cancer screening 
more frequently than men do. For women, a 
better socioeconomic status was associated 
with higher participation rates. Participation 
rates improve with increasing age, mean-
ing that the difference in participation rates 
between women and men becomes small-
er. The current analyses present information 
on specifically targeted population groups 
to promote informed decision-making about 
cancer screening, so that participation rates 
can be improved further. The analyses thus 
provide an important basis for health poli-
cy measures.
Keywords
Health survey · Cancer screening · Colon  
cancer · Breast cancer · Prostate cancer
Inanspruchnahme von Krebsfrüherkennungsuntersuchungen.  
Ergebnisse der Studie zur Gesundheit 
Erwachsener in Deutschland (DEGS1)
Zusammenfassung
Eine wachsende Zahl von Menschen in 
Deutschland nimmt die von der Gesetz-
lichen Krankenversicherung angebote-
nen Krebsfrüherkennungsuntersuchun-
gen (KFU) in Anspruch. Mit Daten der ersten 
Erhebungs welle der Studie zur Gesundheit 
Erwachsener in Deutschland (DEGS1) wur-
den aktuelle Inanspruchnahmeraten ermit-
telt. DEGS1 ist ein bundesweiter Befragungs- 
und Untersuchungssurvey (2008–2011), der 
repräsentative Querschnittsanalysen da-
zu ermöglicht. In DEGS1 wurden die jeweils 
anspruchsberechtigten Personen zur Kennt-
nis, Regelmäßigkeit sowie zur turnusmäßi-
gen Inanspruchnahme von KFU für einzelne 
Krebsarten befragt. Regelmäßig gehen ins-
gesamt etwa 67,2% der Frauen und 40,0% 
der Männer zur KFU. Bei den einzelnen Unter-
suchungen schwanken die Teilnahmeraten 
stark. Frauen nehmen an vielen KFU häufiger 
teil als Männer, und eine bessere sozioökono-
mische Lage war bei ihnen mit höheren Teil-
nahmeraten assoziiert. Im Alter verbessern 
sich die Teilnahmeraten und nähern sich 
zwischen den Geschlechtern an. Die Auswer-
tungen geben Hinweise auf Bevölkerungs-
gruppen, die gezielt angesprochen und darin 
unterstützt werden sollten, eine infor mierte 
Entscheidung zur KFU zu treffen, um die Teil-
nahmeraten weiter zu erhöhen. Sie stellen 
damit eine wichtige Grundlage für gesund-
heitspolitische Maßnahmen dar.
Schlüsselwörter
Gesundheitssurvey · Krebsfrüherkennung · 
Darmkrebs · Brustkrebs · Prostatakrebs
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the proportion increases with age. Among 
women, there are hardly any differences 
with regard to age groups. The sex dif-
ference in the elderly is remarkable: The 
proportion of 60–69- and 70–79-year-old 
women who used the early detection of 
skin cancer is lower than for men. There 
is no social gradient for screening partic-
ipation.
Early detection of colon cancer
In all, 45.4% of women and 24.8% of men 
aged between 50 and 54 years received a 
test strip for detecting blood in the stool 
(haemoccult test) for the purpose of early 
detection of colon cancer (. Tab. 4) dur-
ing the last 12 months before the inter-
view. The majority of interviewed wom-
en and men stated that they submitted this 
test strip with the required stool samples 
for examination (84.8%). There is no sig-
nificant influence of the SES on testing be-
haviour either for men or for women in 
this age group.
From the age of 55 years, the haemoc-
cult test is recommended at an inter-
val of 2 years for those who do not wish 
an early-detection colonoscopy offered 
from that age. Overall, 54.2% of women 
and 51.6% of men aged 55 years and old-
er indicated that they received the test 
within the 2 years preceding the inter-
view (. Tab. 4). Almost all of them sub-
sequently submitted the test strip for ex-
amination (96.0%). Among women, there 
is an influence of age on the frequency of 
participation: with increasing age, few-
er women participate. When stratified by 
age groups, there is no social gradient in 
participation for both women and men.
From the age of 55 years, policyholders 
are entitled to preventive colonoscopies. 
In case of normal results, they are enti-
tled to a repeat colonoscopy after 10 years. 
Colonoscopies are carried out both as part 
of cancer screening tests (early-detection 
colonoscopy) and also to clarify concrete 
cases of suspected disease or as part of 
aftercare services. However, DEGS1 did 
not ask why the last colonoscopy was un-
dertaken. This means that whereas the 
DEGS1 data can be used to describe over-
all the degree to which people make use 
of colonoscopies for the target group of 
those aged 55 years and over, this is not 
the case for the subset of early-detection 
colonoscopies. More than half of wom-
en (55.4%) and men (54.1%) eligible for 
the service had a colonoscopy within the 
last 10 years (see . Tab. 4). Women and 
men aged between 55 and 59 years had 
at least one colonoscopy (women 47.2%, 
men 44.9%). One possible reason is that 
they had just reached the age of eligibili-
ty. There is no clear gradient with regard 
to SES.
Early detection of cervical cancer
Every second woman from the age of 
20 years (52.8%) had a cervical smear test 
for early detection of cervical cancer with-
in the 12 months preceding the interview. 
Women aged between 40 and 49 years 
had the highest participation rate (60.7%), 
whereas the lowest rate was found among 
women aged 70 years and older (35.5%; 
. Tab. 5). A significant influence of the 
SES is present: 30- to 59-year-old wom-
en with a low SES show lower participa-
tion rates in cancer screening (within the 
12 months prior to the interview) than 
women with a high SES.
Early detection of breast cancer
Almost two thirds of women from the 
age of 30 years (62.1%) reported that they 
had undergone a clinical breast exami-
nation in the 12 months before the inter-
view. The highest participation rates were 
observed for women in the age groups of 
40–49 and 50–59 years (69.9% and 69.1%, 
respectively), the lowest for women aged 
70 years and older (44.9%; . Tab. 5). SES 
Tab. 3 Regular participation in cancer screening tests, categorised by sex, age groups and socioeconomic status 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































has a clear impact here: with the exception 
of women aged 60–69 years, women with 
a low SES show significantly lower par-
ticipation rates in this particular screen-
ing test over the 12 months preceding the 
interview than women of high SES. Be-
tween the ages of 50–69 years, women are 
eligible for biennial radiological breast ex-
aminations as part of the national mam-
mography screening programme. Mam-
mographies can be carried out as part of a 
cancer screening programme, to clear up 
a concrete suspected diagnosis or as part 
of aftercare. DEGS1 asked for the reason 
for the last mammography to ensure that 
the existing data could be used to provide 
an overview of women’s participation in 
mammography overall and also of par-
ticipation in the national mammography 
screening programme. Overall, 71.3% of 
women in the target group aged between 
50 and 69 years stated that they had had a 
mammography within the last 24 months. 
Slightly more women aged 60–69 years 
were examined than in the younger age 
groups (74.9% vs. 68.5%; . Tab. 5). There 
is no SES gradient.
To state their reasons for participating 
in their last mammography, participants 
could choose from several answer catego-
ries (multiple answers were possible). The 
most common reason for the last mam-
mography (within the last 24 months) was 
an invitation by the national mammogra-
phy screening programme (65.4%). This 
means that about half of all eligible wom-
en between 50 and 69 years of age were 
reached by the national mammography 
screening programme and underwent the 
examination (49.2%).
Early detection of prostate cancer
Only 38.9% of eligible men from the age of 
45 years underwent a palpation test with-
in the last 12 months before the interview. 
The participation rate increased with age. 
Among men aged 70–79 years, the par-
ticipation rate reached 55.5%. However, 
the proportion of those who underwent 
examination in the 12 months preceding 
the interview was very low, especially for 
younger men (20.2%; . Tab. 6). There is 
no SES gradient.
The PSA blood test is also used for the 
diagnosis of prostate carcinoma. Howev-





























































































































































































































































































































































































































































































































































































































































































































































































































equivocally attributed to prostate cancer, 
as there can also be other causes such as 
inflammation. Therefore, statutory health 
insurance does not offer the PSA test for 
early detection of prostate cancer as part 
of the cancer screening programme. In 
this case, men must pay for the test them-
selves as an individual health service [20]. 
However, if the palpation test result is pos-
itive, it is often followed up by a PSA anal-
ysis. In all, 30.6% of men aged 45 years 
and over indicated that they had their PSA 
level checked within the last 12 months.
The majority of men (89.5%) who had 
undergone palpation of the prostate in 
the last 12 months stated that the PSA lev-
el was also determined within that time 
period. However, the two examinations 
may have been performed separately and 
in any order. This aspect was not covered 
by DEGS1. Overall, 10.1% of men aged 
45 years or over stated that the PSA lev-
el was tested but no palpation of the pros-
tate took place (data not shown). PSA test-
ing is clearly influenced by a person’s SES: 
significantly fewer men of low SES under-
went this examination than men of medi-
um or high SES. When stratified by age, 
this effect is evident only in 60- to 79-year-
old men and only for the low compared to 
the highest SES group. Participation in an 
examination by palpation was not influ-
enced by SES.
Discussion
Analysis of the data presented here shows 
that a vast majority of adults in Germa-
ny, who are the target group of statutory 
health insurance for cancer screening pro-
grammes, are aware of the recommenda-
tion to participate in such programmes. 
According to these data, about two thirds 
of women and less than half of the men 
regularly undergo cancer screening. Par-
ticipation rates in individually offered 
cancer screening tests differ to a high de-
gree. There are many reasons for this, and 
they have to do, for example, with organ-
isation (invitation to attend mammo-
graphy screening versus individuals tak-
ing the initiative to make an appointment 
themselves in the case of other screening, 
e.g. prostate cancer screening) and level of 
awareness (skin cancer screening has on-
ly been offered by statutory health insur-
ance since 2008). Overall more women 
than men participate in cancer screening. 
With increasing age, participation rates 
rise, especially among men, and the dif-
ference between the sexes decreases. This 
probably has to do with rising numbers 
of doctor visits and a resulting increase in 
participation probability [7, 8]. SES has an 
influence on awareness and participation 
in early-detection programmes, especially 
among women. For age-stratified data, the 
status effect often remains among wom-
en: more educated women with a higher 
income more frequently undergo cancer 
screening. Among men, status effects are 
less frequent and less pronounced.
Information on adult participation 
in cancer screening programmes can be 
obtained from population-related in-
terviews and from the payment data of 
health insurers. Interviews have the ad-
vantage that in the analysis, informa-
tion on participation can be related to 
individuals. In addition, interviews per-
mit inclusion of supplementary ques-
tions and issues related to participation 
in cancer screening, for example, rea-
sons for non-participation. On the other 
hand, statements that participants make 
about their own participation in screen-
ing programmes are subject to a certain 
degree of uncertainty. In other surveys 
on cancer screening participation rates, 
such differences have also been observed 
and discussed [21, 22]. A comparison of 
the results on cancer screening participa-
tion from DEGS1 with other data sources 
shows a good correlation with other in-
terview data and a certain degree of de-
viation in prevalence when compared to 
the payment data. With the exception of 
the mammography, DEGS1 did not ask 
the reason for participation in individual 
cancer screening tests. The listed exami-
nations are also offered free of charge for 
statutory health insurance policyholders 
given the relevant indication, for exam-
ple, to investigate a suspected disease. In 
that case, the fees charged by the attend-
ing physician are different. This can re-
sult in differences when comparing the 
DEGS1 data with payment information. 
For example, regular participation in 
the offered biennial skin cancer screen-
ing programme is reported to be about 
one quarter in DEGS1 but amounts to 
about 33.3% for women and 31.9% for 
men according to the payment data of 
the Central Research Institute of Ambu-
latory Health Care in Germany [23]. In 
the telephone interview “German Health 
Update” 2010 conducted by the RKI 
(GEDA 2010), every third person inter-
viewed reported that they had participat-
ed in skin cancer screening before [21]. 
In DEGS1, about half of eligible wom-
en and men stated that they had under-
Tab. 6 Regular participation in cancer screening tests intended for men, categorised by age group and socioeconomic status 
(proportion in percent with 95% confidence intervals)
Socioeconomic status Age group in years
  45–49 50–59 60–69 70–79 Total
Prostate palpation  
from 45 years: 
within the last 12 months  
nunweighted =973
Total 20.2 (15.9–25.4) 32.5 (28.7–36.6) 48.8 (44.4–53.2) 55.5 (49.9–60.9) 38.9 (36.5–41.4)
Low 12. 8 (6.1–25.1) 23.8 (16.3–33.4) 44.6 (31.9–58.1) 46.2 (33.9–59.0) 32.1 (26.4–38.4)
Medium 24.1 (17.8–31.9) 33.5 (28.3–39.0) 48.9 (43.1–54.7) 57.2 (50.7–63.4) 40.3 (37.1–43.7)
High 16.8 (10.5–25.9) 38.4 (30.2–47.3) 51.8 (43.5–60.0) 65.5 (55.0–74.7) 42.3 (37.5–47.2)
PSA valuea 
from 45 years: 
within the last 12 months 
nunweighted =785
Total 12.0 (8.4–16.9) 25.0 (290.9–29.6) 40.4 (35.9–45.0) 45.7 (40.3–51.3) 30.6 (28.2–33.1)
Low 7.4 (1.5–29.1) 16.5 (9.6–27.1) 28.6 (18.6–41.4) 31.2 (21.4–43.1) 21.3 (16.9–26.4)
Medium 14.5 (9.4–21.7) 25.0 (19.2–31.9) 38.1 (32.5–43.9) 45.9 (39.1–52.9) 30.4 (27.1–34.0)
High 9.9 (5.5–17.2) 32.9 (25.3–41.6) 53.8 (45.8–61.6) 68.0 (58.3–76.4) 40.0 (35.1–45.1)
aNo examination as part of the cancer screening programme offered by statutory health insurance
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gone a colonoscopy before. In a survey of 
the Lebensblicke Foundation conducted 
in 2010, similar colonoscopy rates were 
found [24]. However, as was the case with 
DEGS1, no distinction was made based 
on the reasons for the colonoscopy. In 
contrast, the payment data for the peri-
od 2003–2011 suggest that only 20% of all 
persons aged between 55 and 74 years had 
a colonoscopy as part of cancer screening 
[25]. According to DEGS1, roughly every 
second woman from the age of 20 years 
had a cervical smear for early detection 
of cancer of the cervix. The Bertelsmann 
Health Monitor showed that in 2007 just 
over 50% of women had participated in 
this programme (within 2 years) [26]. 
About 70% of eligible women report-
ed in DEGS1 that they had had a mam-
mography in the previous 2 years. A sur-
vey among AOK policyholders showed 
an equally high participation rate (ever 
participated) in the year 2007 [27]. How-
ever, in both cases the data provided re-
ferred to mammographies in general, i.e. 
independently of the national mammog-
raphy screening programme that was set 
up in 2005. The evaluation of the mam-
mography screening programme showed 
a participation rate of 53.7% for the time 
period 2008–2009 [28]. In DEGS1, just 
over a third of men stated that they reg-
ularly participated in a prostate screening 
test (palpation examination). Here, too, 
there is relatively good correlation with 
other surveys: In the Bertelsmann Health 
Monitor, just over a third of men report-
ed that they had participated in prostate 
cancer screening (within 2 years) [26]. A 
survey from 2004 on participation rates 
in this cancer screening programme of-
fered by statutory health insurance found 
a regular yearly participation rate of 25% 
[29].
The level of acceptance of these pre-
ventive measures can be estimated on the 
basis of the analyses of cancer screening 
participation. With the help of data col-
lected in DEGS1, the population groups 
that are aware of and regularly participate 
in cancer screening programmes can be 
described in more detail. However, it is al-
so possible to identify groups who are not 
as yet sufficiently informed about cancer 
screening and who so far have made use 
of such services infrequently or not at all. 
With regular health surveys conducted as 
part of health monitoring it will be pos-
sible in future to determine participation 
rates and to make statements on trends, 
also with respect to newly launched or re-
cently expanded screening tests. For the 
purpose of implementing the research re-
sults in practice, it is important not on-
ly to determine who is not participating 
but also why they are not doing so. These 
reasons were determined for skin and co-
lon cancer screening in the GEDA 2010 
telephone interviews of the RKI [21]. In-
dications of what type of support target 
groups need to make an informed deci-
sion are important sources for health pol-
icy planning and can help to further im-
prove participation in cancer screening 
programmes.
An extension of cancer screening is 
planned within the framework of the Na-
tional Cancer Plan, among other mea-
sures. These plans are inspired by the rel-
evant European guidelines [30]. Provid-
ing better information to policyhold-
ers about the benefits and risks of can-
cer screening as well as sending regular 
letters of invitation to improve participa-
tion rates are planned. These measures 
aim to strengthen cancer screening pro-
grammes and, by permitting early can-
cer detection, should help improve the 
chances of survival of those affected and 
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